1 October 2020

Meet us at BIO-Europe 2020, October 26-29

Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.    
1 July 2020

Jeremy Bastid nominated as Chief Executive Officer

Orega Biotech announces the nomination of Jeremy Bastid as Chief Executive Officer (Directeur Général) effective as of July 1st, 2020. “I have worked with Jeremy since the inception of OREGA Biotech” commented Gilles Alberici, President of Octalfa and Chairman of OREGA Biotech. “He has played a prominent role in the development of the company, both on the R&D and the business aspects. No doubt that his promotion as CEO of OREGA Biotech will help the company to further grow”, he added. “I am honored to be appointed new CEO and look forward to leading OREGA Biotech with the support from our Board”, commented Jeremy Bastid. “I am thrilled to lead this remarkable team and I am grateful for our Board’s confidence”.
5 May 2020

Role of IL-17B in cancer reviewed in Frontiers in Immunology

We review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. The emerging role of the IL-17B/IL-17RB pathway in cancer, published in  Frontiers in Immunology and co-authoring Jeremy Bastid, Cécile Dejou, Aurélie Docquier and Nathalie Bonnefoy (OREGA Biotech). The review article is accessible here.    
10 March 2020

PRESS RELEASE – 1st patient treated & 10-y anniversary

– PRESS RELEASE – For immediate release   First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary day   Lyon, France, March 10th, 2020 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today that the first patient has been treated with the anti-CD39 humanized monoclonal antibody IPH5201. As chance would have it, it happened exactly 10 years to the day of inception of OREGA Biotech. “March 9th 2020 is marked special for us since our company was celebrating its 10th anniversary! In 10 years, we have come a long way and we have succeeded in the model we have chosen: that of discovering new targets and together with our partners bringing them to the patients. And on this 10‑year anniversary day the first patient has been dosed with IPH5201, the anti-CD39 monoclonal antibody that we developed in collaboration with Innate Pharma. A nice wink and real pride.”, said Jeremy Bastid, Chief Operating Officer of OREGA Biotech. Download the Press Release online.   About IPH5201 and NCT04261075 clinical trial IPH5201 is now being developed by Innate Pharma in collaboration with AstraZeneca (AZ). The multicenter, open-label, dose-escalation Phase I study (NCT04261075) will evaluate the safety, tolerability, antitumor activity, pharmacokinetics , pharmacodynamics and immunogenicity of IPH5201 alone, or in combination with AZ’s anti-PDL1 monoclonal antibody, durvalumab, with or without AZ’s anti-CD73 monoclonal antibody, oleclumab. More information on the Phase I clinical trial is accessible online.   About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. A new program is underway on a novel potent regulator of anti‑PD1 therapy response in anti‑PD1 refractory syngeneic mouse models. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.   Contact Jeremy Bastid, Chief Operating Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   […]
PRESS RELEASE – 1st patient treated & 10-y anniversary
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more